Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Silvia Martin Lluesma"'
Autor:
Apostolos Sarivalasis, Caroline Boudousquié, Klara Balint, Brian J. Stevenson, Philippe O. Gannon, Emanuela Marina Iancu, Laetitia Rossier, Silvia Martin Lluesma, Patrice Mathevet, Christine Sempoux, George Coukos, Urania Dafni, Alexandre Harari, Michal Bassani-Sternberg, Lana E. Kandalaft
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-10 (2019)
Abstract Background Most ovarian cancer patients are diagnosed at a late stage with 85% of them relapsing after surgery and standard chemotherapy; for this reason, new treatments are urgently needed. Ovarian cancer has become a candidate for immunoth
Externí odkaz:
https://doaj.org/article/32c4093eeb7a4550bc29df185dcfea86
Autor:
Michal Bassani-Sternberg, Antonia Digklia, Florian Huber, Dorothea Wagner, Christine Sempoux, Brian J. Stevenson, Anne-Christine Thierry, Justine Michaux, HuiSong Pak, Julien Racle, Caroline Boudousquie, Klara Balint, George Coukos, David Gfeller, Silvia Martin Lluesma, Alexandre Harari, Nicolas Demartines, Lana E. Kandalaft
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Despite the promising therapeutic effects of immune checkpoint blockade (ICB), most patients with solid tumors treated with anti-PD-1/PD-L1 monotherapy do not achieve objective responses, with most tumor regressions being partial rather than complete
Externí odkaz:
https://doaj.org/article/7a54a5460b79482bb67920b6494b0f01
Autor:
Pelagia G. Tsoutsou, Khalil Zaman, Silvia Martin Lluesma, Laurene Cagnon, Lana Kandalaft, Marie-Catherine Vozenin
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
The association of radiotherapy and immunotherapy has recently emerged as an exciting combination that might improve outcomes in many solid tumor settings. In the context of breast cancer, this opportunity is promising and under investigation. Given
Externí odkaz:
https://doaj.org/article/c61b027391c146a1b74f6d2a0f2bcfa9
Publikováno v:
Vaccines, Vol 6, Iss 4, p 79 (2018)
Although different types of therapeutic vaccines against established cancerous lesions in various indications have been developed since the 1990s, their clinical benefit is still very limited. This observed lack of effectiveness in cancer eradication
Externí odkaz:
https://doaj.org/article/028c8a16178845168da5ccefc0000caa
Publikováno v:
Biomedicines, Vol 4, Iss 2, p 10 (2016)
Epithelial ovarian cancer (EOC) is one important cause of gynecologic cancer-related death. Currently, the mainstay of ovarian cancer treatment consists of cytoreductive surgery and platinum-based chemotherapy (introduced 30 years ago) but, as the di
Externí odkaz:
https://doaj.org/article/7d2636f71c364f5998054500058fdbaf
Autor:
Michele Graciotti, Cheryl Lai-Lai Chiang, Caroline Boudousquié, Lana E. Kandalaft, Alizée J. Grimm, Silvia Martin-Lluesma
Publikováno v:
Current opinion in biotechnology. 65
New treatments are urgently needed in patients with ovarian cancer (OC), as diagnosis is delayed in many instances, resulting in 85% recurrence of the disease following surgery and standard chemotherapy. OC is considered to be an immunological type o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c6beb9f62b69c2a89fd858f14dbffe
https://pubmed.ncbi.nlm.nih.gov/32334152
https://pubmed.ncbi.nlm.nih.gov/32334152
Autor:
Silvia Martin Lluesma, Urania Dafni, Alexandre Harari, Apostolos Sarivalasis, Christine Sempoux, Klara Balint, Philippe O. Gannon, George Coukos, Michal Bassani-Sternberg, Lana E. Kandalaft, Emanuela Marina Iancu, Laetitia Rossier, Patrice Mathevet, Caroline Boudousquié, Brian Stevenson
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-10 (2019)
Journal of translational medicine, vol. 17, no. 1, pp. 391
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-10 (2019)
Journal of translational medicine, vol. 17, no. 1, pp. 391
Background Most ovarian cancer patients are diagnosed at a late stage with 85% of them relapsing after surgery and standard chemotherapy; for this reason, new treatments are urgently needed. Ovarian cancer has become a candidate for immunotherapy by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cc31d8de61f536998863325ee232e96
http://europepmc.org/articles/PMC6880492
http://europepmc.org/articles/PMC6880492
Autor:
Klara Balint, George Coukos, Antonia Digklia, Justine Michaux, Michal Bassani-Sternberg, Florian Huber, Caroline Boudousquié, Nicolas Demartines, Lana E. Kandalaft, Silvia Martin Lluesma, HuiSong Pak, Brian Stevenson, Christine Sempoux, Anne-Christine Thierry, David Gfeller, Alexandre Harari, D. Wagner, Julien Racle
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology
Frontiers in Immunology
Despite the promising therapeutic effects of immune checkpoint blockade (ICB), most patients with solid tumors treated with anti-PD-1/PD-L1 monotherapy do not achieve objective responses, with most tumor regressions being partial rather than complete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e89808297c022651f6decae11320821d
https://pubmed.ncbi.nlm.nih.gov/31440238
https://pubmed.ncbi.nlm.nih.gov/31440238
Publikováno v:
Biomedicines, Vol 4, Iss 2, p 10 (2016)
Biomedicines
Biomedicines
Epithelial ovarian cancer (EOC) is one important cause of gynecologic cancer-related death. Currently, the mainstay of ovarian cancer treatment consists of cytoreductive surgery and platinum-based chemotherapy (introduced 30 years ago) but, as the di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f3e3434f33c14cc72df03133a3378c0
http://www.mdpi.com/2227-9059/4/2/10
http://www.mdpi.com/2227-9059/4/2/10
Autor:
Silvia Martin-Lluesma, Bruno Goud, Sandrine Moutel, Franck Perez, Thomas E. Kreis, Aurélien Roux, Clément Nizak
Publikováno v:
Traffic. 4:739-753
Generation of specific antibodies against enriched subcellular fractions is a powerful strategy to identify and characterize cellular components. We show that recombinant antibodies can be selected in vitro by phage display against complex subcellula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f741f131793bf4d4ac171e4cc9e3749
https://doi.org/10.1034/j.1600-0854.2003.00132.x
https://doi.org/10.1034/j.1600-0854.2003.00132.x